Isofol Medical AB Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.09.20	55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study (PR Newswire)
01.09.20	Strengthened patent protection for arfolitixorin in Japan (PR Newswire)
13.08.20	Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan (PR Newswire)
04.08.20	Isofol's CEO Ulf Jungnelius has subscribed for all warrants (PR Newswire)
10.07.20	AGENT Study Update With Regards to COVID-19 (PR Newswire)
03.06.20	Isofol's Rights Issue Oversubscribed (PR Newswire)
14.05.20	Isofol Publishes Prospectus in Connection With the Fully Guaranteed Preferential Rights Issue of Approximately SEK 150 Million (PR Newswire)
07.05.20	Isofol's Board of Directors Resolve on a Fully Guaranteed Preferential Rights Issue of Approximately SEK 150 Million (PR Newswire)
05.05.20	Isofol's Drug Candidate Arfolitixorin Receives Additional Clinical Patent Approval in the United States (PR Newswire)
30.03.20	Isofol Announces its Intention to Carry Out a Fully Guaranteed Preferential Rights Issue of Approximately SEK 150 Million and a Potential Over-allotment Option of up to Approximately SEK 30 Million (PR Newswire)
30.03.20	Gene Expression Data From New Analysis Method Supports That a Larger Proportion of Patients will Benefit From Arfolitixorin (PR Newswire)
18.02.20	The First Patient Included in Japan in Isofol's Phase 3 AGENT Study (PR Newswire)
30.01.20	Gene Expression Analysis Method has Been Validated by a Commercial Laboratory (PR Newswire)
30.01.20	Isofol Medical: The Phase 1/2a Study ISO-CC-005 is Completed (PR Newswire)
30.01.20	Isofol Medical: Over 200 Patients Now Randomized in the Global Phase 3 AGENT Study (PR Newswire)
24.01.20	The First Patient Included in Australia in Isofol's Phase 3 AGENT Study (PR Newswire)
20.12.19	Patent Approved in Japan for Isofol's Drug Candidate Arfolitixorin (PR Newswire)
13.11.19	Isofol's Board Appoints Dr. Jarl Ulf Jungnelius as New CEO of the Company (PR Newswire)
18.10.19	Isofol Receives Positive Feedback From PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer (PR Newswire)
29.09.19	Isofol Announces Presentation on the Global Phase 3 Study of Arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress (PR Newswire)
12.09.19	Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress (PR Newswire)
15.08.19	Isofol Announces Management Team Evolution With Appointment of Dr. Roger Tell as Chief Medical Officer (PR Newswire)
15.07.19	Isofol Announces Recent Advisory Board Meeting Covering Development Plan for Arfolitixorin (PR Newswire)
10.06.19	Isofol Announces Election of Three New Board Members (PR Newswire)
21.05.19	Isofol's Drug Candidate Arfolitixorin Receives Clinical Patent Approval in the United States (PR Newswire)
08.05.19	Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with Arfolitixorin (PR Newswire)
01.02.19	Isofol Reports All Employees Participate in Newly Created Share Warrant Program (PR Newswire)
17.01.19	Isofol Reports Early Tumor Shrinkage in Patients With Colorectal Cancer in Phase 1/2a Open Label Extension Study with Arfolitixorin (PR Newswire)
18.12.18	First Patient Enrolled in Isofol's Pivotal Phase 3 AGENT Study in 1st Line Metastatic Colorectal Cancer (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Isofol Medical AB Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten